Alterations of T-cell-mediated immunity in acute myeloid leukemia.

Oncogene
Zhuoyan LiP Brent Ferrell

Abstract

Acute myeloid leukemia (AML) is a systemic, heterogeneous hematologic malignancy with poor overall survival. While some malignancies have seen improvements in clinical outcomes with immunotherapy, success of these agents in AML remains elusive. Despite limited progress, stem cell transplantation and donor lymphocyte infusions show that modulation of the immune system can improve overall survival of AML patients. Understanding the causes of immune evasion and disease progression will identify potential immune-mediated targets in AML. This review explores immunosuppressive mechanisms that alter T-cell-mediated immunity in AML.

References

Aug 1, 1974·The Journal of Clinical Investigation·E M HershE J Freireich
Nov 1, 1971·The New England Journal of Medicine·E M HershE J Freireich
Nov 8, 2001·The Journal of Immunology : Official Journal of the American Association of Immunologists·A G BugginsW J Hirst
Mar 25, 2006·Nature Reviews. Immunology·Weiping Zou
Sep 2, 2006·Blood·Jerome MoreauxBernard Klein
Jan 26, 2007·Leukemia·A TonksR L Darley
Apr 20, 2007·The Journal of Immunology : Official Journal of the American Association of Immunologists·Anke Kretz-RommelKatherine S Bowdish
Dec 7, 2007·Biochemical and Biophysical Research Communications·Jérôme MoreauxBernard Klein
Sep 9, 2008·Trends in Immunology·Brian T Kawasaki, William L Farrar
May 7, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Miroslaw J SzczepanskiMichael Boyiadzis
Nov 26, 2010·International Journal of Cancer. Journal International Du Cancer·Zhang ShenghuiXu Xi
Jul 9, 2011·Nature Immunology·E John Wherry
Oct 3, 2012·Cytometry. Part B, Clinical Cytometry·Hanna DobrowolskaAdriana I Colovai
Dec 20, 2013·Journal for Immunotherapy of Cancer·Ryan M Teague, Justin Kline
Jun 25, 2014·Leukemia Research·Felix S LichteneggerMarion Subklewe
Aug 12, 2014·Molecular Oncology·Sander KeldermanJohn B A G Haanen
Aug 21, 2014·Current Hematologic Malignancy Reports·Giovanni Barosi
Oct 7, 2014·Leukemia & Lymphoma·Armin Rashidi, Stephen I Fisher
Jul 16, 2015·Journal of Translational Medicine·Gerardo MusuracaSilvia Carloni

❮ Previous
Next ❯

Citations

Aug 18, 2020·BioMed Research International·Zhenyi JinXiuli Wu
Jul 8, 2020·Cancers·Donatella AldinucciNaike Casagrande
Apr 4, 2021·Cancers·Julian SwatlerKatarzyna Piwocka
Apr 4, 2021·Cancers·Stephanie SendkerNaghmeh Niktoreh
Apr 4, 2021·Pharmaceuticals·Laura JimbuMihnea Zdrenghea
Oct 14, 2021·Molecular Biology Reports·Huihui JiangChengming Sun
Nov 7, 2021·Journal of Cellular and Molecular Medicine·Ruonan ShaoYue Lu

❮ Previous
Next ❯

Methods Mentioned

BETA
MDS
flow cytometry

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.